| |
Safety, Pharmacokinetic and Preliminary Antiviral Activity Results from a First-in-Human Study of IDX719, a Pan-Genotypic Novel HCV NS5A Inhibitor
|
| |
| |
Reported by Jules Levin
7th International Workshop on Clinical Pharmacology of Hepatitis Therapy
June 27, 2012
X.J. Zhou, B. Vince, G. Dubuc Patrick, J. Chen, K. Pietropaolo, J. Z. Sullivan-Bolyai and D. Mayers
|
|
| |
| |
|
|
|
